Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy ONCY?
Source: Newsfilter
- Leadership Enhancement: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate, indicating its potential in difficult-to-treat patient populations.
- FDA Designation Approval: Oncolytics secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the initiation of the only immunotherapy registration trial planned for this challenging area, further solidifying its market position.
- Advisory Board Expansion: The company has expanded its Scientific Advisory Board by adding globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, laying the groundwork for accelerated clinical development across multiple indications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONCY
Wall Street analysts forecast ONCY stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.060
Low
3.00
Averages
5.50
High
10.00
Current: 1.060
Low
3.00
Averages
5.50
High
10.00
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Adjusts Clinical Trial Strategy
- Clinical Trial Adjustment: Oncolytics Biotech announced the termination of enrollment in its GOBLET study, shifting focus to registrational and registration-enabling studies, particularly for squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC), aiming to optimize resource allocation and enhance R&D efficiency.
- FDA Meeting Plans: The company plans to meet with the FDA in mid-April to seek regulatory feedback on a single-arm registrational trial for SCAC, which it expects will be sufficient for U.S. approval of pelareorep, paving the way for future market access.
- Cost-Saving Measures: Oncolytics decided to end additional enrollments for the GOBLET Cohort 5 in Germany as part of its cost-saving measures, a decision that will help the company reallocate resources to more promising cancer treatment areas.
- Positive Market Reaction: Following the announcement of this strategic adjustment, Oncolytics Biotech (ONCY) saw its stock price rise, reflecting investor confidence in the company's new focus on SCAC and CRC, which may enhance its competitiveness in the biopharmaceutical market.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is projected to grow from $279.98 billion in 2026 to $748.17 billion by 2035, indicating strong growth potential and reflecting the ongoing demand for cancer treatments.
- Innovation-Driven Revenue: Cancer drug revenues are expected to reach $335.2 billion by 2033, primarily driven by the adoption of targeted therapies and immunotherapy, indicating a significant shift towards more effective treatment options in the industry.
- Clinical Trial Advancements: Oncolytics Biotech is focusing on registrational programs in anal and colorectal cancer, planning to meet with the FDA in mid-April, and expects to secure approval through a clinical trial involving fewer than 100 subjects, showcasing its strategic advantage in rare cancer indications.
- Strong Clinical Results: In third-line anal cancer patients, pelareorep achieved a 29% response rate, while in second-line or later patients, the response rate was 30%, significantly exceeding the benchmark for FDA-approved immunotherapies, highlighting its potential in treatment efficacy.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is projected to grow from $279.98 billion in 2026 to $748.17 billion by 2035, indicating strong growth potential driven by the rising demand for cancer treatments.
- Drug Revenue Forecast: Cancer drug revenues are expected to reach $335.2 billion by 2033, primarily fueled by the adoption of targeted therapies and immunotherapy, highlighting the urgent need for innovative treatment options in the market.
- Clinical Trial Progress: Oncolytics Biotech announced its focus on registrational programs in anal and colorectal cancer, with plans to meet with the FDA in mid-April 2026 to seek approval in this rare cancer indication, demonstrating its strategic positioning in clinical research.
- Leadership Changes: Oncolytics Biotech recently appointed John McAdory as EVP of Strategy and Operations and Yujun Wu as Head of Biostatistics, further strengthening the company's leadership capabilities and competitive edge in the oncology treatment sector.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Surge in Clinical Trials: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, highlighting the drug's potential market value of up to $5 billion in a challenging cancer segment.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, reflecting the company's commitment to expanding its clinical development efforts and enhancing operational capabilities.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Clinical Trial Surge: In 2024, over 2,100 oncology clinical trials were initiated globally, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 10% response rate of standard treatments, which will expedite its approval process.
- Significant Survival Extension: Patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, suggesting a potential market value of $3 billion to $5 billion for this difficult-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expansion plans, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, demonstrating the company's commitment to advancing its clinical development initiatives.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
- Clinical Trial Surge: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, indicating a potential market value of $3 billion to $5 billion for this hard-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expanding programs, demonstrating the company's commitment to accelerating product development and enhancing management capabilities for future clinical trials.
See More
Oncolytics Biotech Adjusts Clinical Trial Strategy
- Clinical Trial Adjustment: Oncolytics Biotech announced the termination of enrollment in its GOBLET study, shifting focus to registrational and registration-enabling studies, particularly for squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC), aiming to optimize resource allocation and enhance R&D efficiency.
- FDA Meeting Plans: The company plans to meet with the FDA in mid-April to seek regulatory feedback on a single-arm registrational trial for SCAC, which it expects will be sufficient for U.S. approval of pelareorep, paving the way for future market access.
- Cost-Saving Measures: Oncolytics decided to end additional enrollments for the GOBLET Cohort 5 in Germany as part of its cost-saving measures, a decision that will help the company reallocate resources to more promising cancer treatment areas.
- Positive Market Reaction: Following the announcement of this strategic adjustment, Oncolytics Biotech (ONCY) saw its stock price rise, reflecting investor confidence in the company's new focus on SCAC and CRC, which may enhance its competitiveness in the biopharmaceutical market.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is projected to grow from $279.98 billion in 2026 to $748.17 billion by 2035, indicating strong growth potential and reflecting the ongoing demand for cancer treatments.
- Innovation-Driven Revenue: Cancer drug revenues are expected to reach $335.2 billion by 2033, primarily driven by the adoption of targeted therapies and immunotherapy, indicating a significant shift towards more effective treatment options in the industry.
- Clinical Trial Advancements: Oncolytics Biotech is focusing on registrational programs in anal and colorectal cancer, planning to meet with the FDA in mid-April, and expects to secure approval through a clinical trial involving fewer than 100 subjects, showcasing its strategic advantage in rare cancer indications.
- Strong Clinical Results: In third-line anal cancer patients, pelareorep achieved a 29% response rate, while in second-line or later patients, the response rate was 30%, significantly exceeding the benchmark for FDA-approved immunotherapies, highlighting its potential in treatment efficacy.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is projected to grow from $279.98 billion in 2026 to $748.17 billion by 2035, indicating strong growth potential driven by the rising demand for cancer treatments.
- Drug Revenue Forecast: Cancer drug revenues are expected to reach $335.2 billion by 2033, primarily fueled by the adoption of targeted therapies and immunotherapy, highlighting the urgent need for innovative treatment options in the market.
- Clinical Trial Progress: Oncolytics Biotech announced its focus on registrational programs in anal and colorectal cancer, with plans to meet with the FDA in mid-April 2026 to seek approval in this rare cancer indication, demonstrating its strategic positioning in clinical research.
- Leadership Changes: Oncolytics Biotech recently appointed John McAdory as EVP of Strategy and Operations and Yujun Wu as Head of Biostatistics, further strengthening the company's leadership capabilities and competitive edge in the oncology treatment sector.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Surge in Clinical Trials: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, highlighting the drug's potential market value of up to $5 billion in a challenging cancer segment.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, reflecting the company's commitment to expanding its clinical development efforts and enhancing operational capabilities.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Clinical Trial Surge: In 2024, over 2,100 oncology clinical trials were initiated globally, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 10% response rate of standard treatments, which will expedite its approval process.
- Significant Survival Extension: Patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, suggesting a potential market value of $3 billion to $5 billion for this difficult-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expansion plans, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, demonstrating the company's commitment to advancing its clinical development initiatives.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
- Clinical Trial Surge: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, indicating a potential market value of $3 billion to $5 billion for this hard-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expanding programs, demonstrating the company's commitment to accelerating product development and enhancing management capabilities for future clinical trials.
See More
